What exactly will Warp Sciences offer first?

Its initial service focuses on lead optimization analog synthesis, making variations of molecules that scientists can compare while searching for a drug candidate.

Does Warp Sciences develop its own drugs?

No. The company says it has no proprietary drug pipeline and instead builds automated labs and infrastructure for customers who retain control of their drug programs.

Who leads Warp Sciences?

Co-founder and CEO Kevin Weil was most recently chief product officer and vice president of science at OpenAI. The founding team also includes Solomon Reisberg, Manohar Paluri and DJ Patil.

RoboticsAI in HealthcareAI Business & IndustryThe Robot Report3h agoOct 29, 2026, 04:00 JST

Warp Sciences exits stealth with $215 million for U.S. chemistry CRO

Send on LINE

3 Key Points

What happened
Warp Sciences emerged from stealth with $215 million in funding, led by Lightspeed, to build a U.S.-based chemistry CRO pairing chemists, robotics and AI.
Why it matters
The South San Francisco startup aims to give drug researchers faster access to compounds and more control over where sensitive research takes place.

WHO IT HITSU.S. biotech and pharmaceutical research teams that rely on outside chemistry partners for drug discovery stand to gain an alternative domestic supplier, though the service is still at an early stage.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Get these free every morning

Context & Analysis

Warp Sciences is positioning itself at the intersection of two trends the company cites: the push to generate real-world experimental data for AI, and the desire for sovereign biotechnology capacity in the U.S. Its founding team brings experience from OpenAI, Meta and other technology and healthcare organizations, and early hires add robotics backgrounds from companies such as Genesis, Skild AI and 1X Technologies. The company argues that chemistry and biology advance when researchers make something, test it and learn from the result, and that AI for science needs a closer connection to physical lab work. Warp says it will not develop drugs of its own, instead providing the infrastructure for customers who determine which molecules to pursue. Whether that model delivers the speed and IP protection it promises will depend on how well its automated labs perform in practice.

FAQ

What exactly will Warp Sciences offer first?: Its initial service focuses on lead optimization analog synthesis, making variations of molecules that scientists can compare while searching for a drug candidate.
Does Warp Sciences develop its own drugs?: No. The company says it has no proprietary drug pipeline and instead builds automated labs and infrastructure for customers who retain control of their drug programs.
Who leads Warp Sciences?: Co-founder and CEO Kevin Weil was most recently chief product officer and vice president of science at OpenAI. The founding team also includes Solomon Reisberg, Manohar Paluri and DJ Patil.

The Robot ReportRead Original Article

Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.